Prostate158 - An expert-annotated 3T MRI dataset and algorithm for prostate cancer detection
Prostate158 - An expert-annotated 3T MRI dataset and algorithm for prostate cancer detection
2025-11-22https://doi.org/10.1148/atlas.1763845915263
71
Overview
Schema Version
https://atlas.rsna.org/schemas/2025-11/model.json
Name
Prostate158 - An expert-annotated 3T MRI dataset and algorithm for prostate cancer detection
Link
https://doi.org/10.1016/j.compbiomed.2022.105817
Indexing
Keywords: Prostate cancer, Deep learning, Machine learning, Artificial intelligence, Magnetic resonance imaging, Biparametric prostate MRI
Content: OI, GU, MR, BQ
Author(s)
Lisa C. Adams
Marcus R. Makowski
Günther Engel
Maximilian Rattunde
Felix Busch
Patrick Asbach
Stefan M. Niehues
Shankeeth Vinayahalingam
Bram van Ginneken
Geert Litjens
Keno K. Bressem
Organization(s)
Charité – Universitätsmedizin Berlin
Berlin Institute of Health at Charité – Universitätsmedizin Berlin
Technical University of Munich
Georg-August University
Radboud University Medical Center
Contact
lisa.christine.adams@gmail.com
Funding
LCA is grateful for her participation in the BIH Charité – Junior Clinician and Clinician Scientist Program and KKB is grateful for his participation in the BIH Charité Digital Clinician Scientist Program, all funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health.
Ethical review
All contributions to this study were approved by the institutional ethics committee, including a waiver of informed consent, and performed in accordance with data protection policy.
Comments
This study presents trained models for automatic segmentation of anatomical zones and areas of suspected prostate cancer in biparametric 3.0 T MRI. The training dataset, training code, and model weights are publicly available.
Date
Published: 2022-07-11
Model
Architecture
U-ResNet consisting of six down-sampling blocks and five up-sampling blocks. Each down-sampling block had four convolutional layers, batch normalization, dropout (15%), and PReLU activation. Up-sampling blocks used transposed convolution and convolutional layers with batch normalization, dropout, and PReLU. Trained for 500 epochs with Novograd optimizer, batch size of two, weight decay of 0.01, and one-cycle learning rate scheduler (initial 0.001). Loss function combined soft Dice similarity coefficient and cross-entropy.
Availability
The models are publicly available to other researchers along with all segmentation masks at https://github.com/kbressem/prostate158. The test set is not available for download to prevent overfitting, but trained models can be evaluated on the test set using the Grand Challenge platform (https://prostate158.grand-challenge.org).
Clinical benefit
Improved lesion detection, targeted biopsy planning, radiotherapy planning, improved volume estimation for disease progression assessment, computational detection of prostate zones and prostate cancer.
Clinical workflow phase
Diagnosis
Degree of automation
Fully automated deep learning pipeline.
Indications for use
Segmentation of anatomical zones (central gland, peripheral zone) and suspicious lesions for prostate cancer (PI-RADS score ≥ 4) in biparametric 3.0 T MRI.
Input
Biparametric 3T prostate MRIs, specifically T2-weighted (T2w) sequences and diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps. For anatomical zones, axial T2w sequences were used. For tumor segmentation, T2w, ADC, and DWI sequences were used as concatenated input.
Instructions
The code to reproduce the training can be found at https://github.com/kbressem/prostate158. Images were pre-processed using intensity normalization (N4ITK), resampling to isotropic voxel spacing of 0.5 × 0.5 × 0.5 mm, and center cropping (removing 20% of image margins). During inference, batch size was reduced to one, and sliding window inference (96 × 96 x 96 voxels with 50% overlap) was used. Prediction maps were one-hot encoded, keeping only the largest connected component for each class.
Limitations
Comparatively small sample size (158 patients). Lack of dynamic contrast-enhanced (DCE) sequences. Only PI-RADS 4 and 5 lesions were segmented as cancerous lesions, potentially limiting comparability with studies including PI-RADS 3. MRI scanners were from the same vendor (Siemens) and all MRIs had the same in-plane resolution, which could limit generalizability to datasets from different manufacturers. The model was largely trained with segmentations from a single rater, potentially reflecting personal biases and affecting performance against other raters.
Output
Description: Pixelwise segmentations for the central gland (central zone and transitional zone), peripheral zone, and prostate cancer (PCa) lesions (defined as PCa suspicious areas with a PI-RADS score of ≥ 4).
Reproducibility
The study openly published all training data, all code, and all model weights, making the research fully reproducible.
Use
Intended: Prostate segmentation, Prostate cancer detection, Volume estimation, Radiotherapy planning, Biopsy planning
Out-of-scope: PI-RADS 3 lesion segmentation, DCE MRI analysis
User
Intended: Radiologist, Oncologist, Urologist, Researcher